A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L01A ALKYLATING AGENTS
|
L01B ANTIMETABOLITES
|
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
|
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
|
L01E PROTEIN KINASE INHIBITORS
|
L01EA BCR-ABL tyrosine kinase inhibitors [DG:DG03161]
|
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors [DG:DG03162]
|
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors [DG:DG03159]
|
L01ED Anaplastic lymphoma kinase (ALK) inhibitors [DG:DG03136]
|
L01EE Mitogen-activated protein kinase (MEK) inhibitors [DG:DG03137]
|
L01EF Cyclin-dependent kinase (CDK) inhibitors [DG:DG03138]
|
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors [DG:DG03160]
|
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors [DG:DG03158]
|
L01EJ Janus-associated kinase (JAK) inhibitors
|
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
|
L01EL Bruton's tyrosine kinase (BTK) inhibitors [DG:DG02022]
|
L01EL01 Ibrutinib
|
D10223 Ibrutinib (JAN/USAN) <JP/US>
|
L01EL02 Acalabrutinib [DG:DG03089]
|
L01EL03 Zanubrutinib
|
L01EL04 Orelabrutinib
|
L01EL05 Pirtobrutinib
|
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors [DG:DG03139]
|
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
|
L01EX Other protein kinase inhibitors
|
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
|
L01X OTHER ANTINEOPLASTIC AGENTS
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|